Acute myocardial infarction: Antithrombotic therapy
- Richard C. Becker MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The treatment of acute myocardial infarction is centered on pharmacology-based strategies designed to prevent or attenuate thrombotic processes occurring within the coronary arterial system. Antithrombotic therapies used currently in clinical practice represent the "fruits of labor" derived from randomized trials and carefully constructed patient management guidelines.
- Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung and Blood Diseases. Bethesda, MD: National Institutes of Health. National Heart, Lung and Blood Institute; 2002.
- Hoffman M, Monroe III DM: A cell-based model of hemostasis. Thromb Haemost 2001, 85:958–965. An ability to understand the biological constructs for hemostasis and pathologic intravascular thrombosis provides distinct targets for pharmacologic intervention
- Becker RC, Harrington R: Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II. Am Heart J 1991, 121:627–640. CrossRef
- Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 1994, 308:81–106.
- Collaborative overview of randomized trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 1994, 308:159–168.
- Collaborative overview of randomized trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 1994, 308:235–246.
- Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 2002, 324:71–86. A large body of evidence firmly supports platelet-derived therapy in atherosclerotic vascular disease.
- Antman EM, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999, 99:2720–2732.
- Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group [no authors listed]. Circulation 2000, 101:2788–2794.
- Brener SJ, Zeymer U, Adgey AAJ, et al.: Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The integrilin and low-dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) Trial. J Am Coll Cardiol 2002, 39:377–386. CrossRef
- Antman EM, Louwerenburg HW, Baars HF, et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002, 105:r27-r34. CrossRef
- Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction [no authors listed]. Lancet 2001, 358:605–613.
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: GUSTO V randomised trial. The GUSTO V Investigators [no authors listed]. Lancet 2001, 357:1905–1914.
- Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999, 100:1016–1030.
- Granger CB, Hirsh J, Califf RM, et al.: Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation 1996, 93:870–878.
- Ross AM, Molhock P, Lundergan C, et al.: A randomized comparison of low-molecular-weight heparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART II). Circulation 2001, 104:648–652.
- Coussement PK, Bassand J-P, Convens C, et al.: A synthetic factor-Xa inhibitor as adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE Study. Eur Heart J 2001, 22:1716–1724. CrossRef
- Cannon CP, McCabe CH, Henry TD, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tPA and aspirin for acute myocardial infarction: Results of TIMI 5. J Am Coll Cardiol 1994, 23:993–1003. CrossRef
- Thrombin-specific anticoagulation with bivalirudin versus heparin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial. The HERO Investigators [no authors listed]. Lancet 2001, 358:1855–1863.
- Weaver WD, Simes RJ, Betriu A, et al.: Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997, 278:2093–2098. CrossRef
- Grines CL, Cox DA, Stone GW, et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999, 314:1949–1956. CrossRef
- Maillard L, Hamon M, Khalife K, et al.: A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000, 35:1729–1736. CrossRef
- Montalescot G, Barragan P, Wittenberg O, et al.: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344:1895–1903. CrossRef
- Stone GW, Grines CL, Cox DA, et al.: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957–966. CrossRef
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable angina to prevent Recurrent Events trail investigators[no authors listed]. N Engl J Med 2001, 345:494–502.
- Schömig A, Neuman F-J, Kastrati A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after placement of coronary artery stents. N Engl J Med 1996, 334:1084–1089. CrossRef
- Leon MB, Bain DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic drug regimens after coronary stenting. Start Anticoagulant Restenosis Study Investigators. N Engl J Med 1998, 339:1665–1671. CrossRef
- Braunwald E, Antman EM, Beasky JE, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2002, 40:1366–1374. Current evidence-based guidelines endorsed by the American College of Cardiology and the American Heart Association. CrossRef
- Boersma E, Pieper KS, Steyerberg EW, et al.: Predictors of outcomes in patients with acute coronary syndromes without persistent ST segment elevation. Results from the international trial of 9461 patients. Circulation 2000, 101:2557–2567.
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. The GUSTO IV-ACS Investigators [no authors listed]. Lancet 2001, 357:1915–1924. The trial’s findings established, for platelet GP IIb/IIIa receptor antagonists and potentially for other platelet antagonists as well, a "threshold" level of inhibition that must be achieved and maintained to derive clinical benefit.
- Becker RC, Bovill EG, Seghatchian MJ, Samama MM: Pathobiology of thrombin in acute coronary syndromes. Am Heart J 1998, 136:519–531. CrossRef
- Low molecular weight heparin during instability in coronary artery disease. The FRISC Study Group [no authors listed]. Lancet 1996, 347:561–568.
- Klein W, Buchwald A, Hillis SE, et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study. Circulation 1997, 96:61–68.
- Cohen M, Demers C, Gurfunkel EP, et al.: A comparison of low molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q wave Coronary Events Study Group. N Engl J Med 1997, 337:447–452. CrossRef
- Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) IIb Trial. Circulation 1999, 100:1593–1601.
- Antman EM, Cohen M, McCabe C, et al.: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI IIB and ESSENCE. Eur Heart J 2002, 23:308–314. CrossRef
- Goodman S: Results of the INTERACT study. Paper presented at the American College of Cardiology 51st Scientific Sessions. Atlanta, GA; March 17–20, 2002.
- Ferguson JJ: Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. J Invas Cardiol 2000, 12(supplE):E10-E13.
- Dyke CK, Becker RC, Kleinman NS, et al.: First experience with direct factor Xa inhibition in patients with stable coronary artery disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002, 105:2385–2391. CrossRef
- Becker RC, Spencer FA, Gibson M, et al.: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics following enoxaparin administration in non-ST segment elevation acute coronary syndromes. Am Heart J 2002, 143:753–759. CrossRef
- Acute myocardial infarction: Antithrombotic therapy
Current Treatment Options in Cardiovascular Medicine
Volume 5, Issue 1 , pp 3-11
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, 55 Lake Avenue North, 01655, Worcester, MA, USA